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While  the recent  advent  of  new  technologies  in  biology  such  as DNA  microarray  and  next-
generation  sequencer  has given  researchers  a  large  volume  of  data  representing  genome-
wide biological  responses,  it is not  necessarily  easy  to derive  knowledge  that  is  accurate
and  understandable  at the  same  time.  In this  study,  we applied  the  Classiﬁcation  Based
on  Association  (CBA)  algorithm,  one  of the  class  association  rule  mining  techniques,  to  the
TG-GATEs database,  where  both  toxicogenomic  and  toxicological  data  of more  than  150eywords:
icroarray
oxicogenomics
lass association rule mining
BA
compounds  in rat  and human  are  stored.  We  compared  the generated  classiﬁers  between
CBA  and  linear  discriminant  analysis  (LDA)  and  showed  that  CBA  is superior  to LDA  in terms
of both  predictive  performances  (accuracy:  83%  for  CBA  vs.  75%  for  LDA,  sensitivity:  82%  for
CBA vs. 72%  for  LDA,  speciﬁcity:  85%  for CBA  vs.  75%  for LDA)  and  interpretability.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe CC  B
. Introduction
New technologies such as DNA microarray and next-
eneration sequencer have allowed researchers to learn
iological phenomena in genome or transcriptome levels.
specially in toxicology, these new technologies have led
o  a new subdiscipline, termed toxicogenomics. Toxicoge-
omics is concerned with the identiﬁcation of potential
uman and environment toxicants, and their putative
echanisms of action, through the use of genomics
esources [1]. For example, by evaluating and character-
zing differential gene expressions, in humans or animals,
fter  exposure to drugs, it is possible to use complex
xpression patterns to predict toxicological outcomes and
o  identify mechanisms involved with or related to the
oxic  event [2]. Traditionally, to construct a such pre-
ictive classiﬁer, techniques in machine learning such as
∗ Corresponding author. Tel.: +81 06 6210 7028.
E-mail address: keisuke.nagata@astellas.com (K. Nagata).
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214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
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k-nearest neighbors, linear discriminant analysis (LDA) and
support  vector machine (SVM) have been mostly used [3].
However,  building a classiﬁer that is accurate and under-
standable at the same time is not necessarily an easy
task. For example, while SVM achieves high classiﬁcation
accuracy, resulting classiﬁers are hard to interpret as vari-
ables  are transformed nonlinearly into a feature space,
and hence difﬁcult to use in order to extract relevant
biological knowledge from it [4]. Very often, predictive
accuracy, understandability, and computational demands
need  to be traded off against one another, because algo-
rithms often compromise one to gain performance in the
other  [5].
In  this study, we applied the classiﬁcation based on
association (CBA) algorithm to toxicogenomic data in an
aim  to build a classiﬁer that is accurate and understandable
at the same time. We  compared its predictive performances
and interpretability of generated classiﬁers with those of
LDA,  which is considered to be one of the most standard
classiﬁcation methods and have a good balance between
accuracy and interpretability.
is is an open access article under the CC BY-NC-ND license
gy Repo1134 K. Nagata et al. / Toxicolo
CBA is one of the class association rule (CAR) mining
algorithms, which integrate association rule mining (ﬁnd-
ing  all the rules existing in the database that satisfy some
constraints) and classiﬁcation rule mining (discovering a
small  set of rules in the database that forms an accurate
classiﬁer) by focusing on mining a special subset of associ-
ation  rules, called class association rules (CARs) [6]. One
of  the advantages of CAR mining algorithms over con-
ventional methods (especially SVM) is its interpretability,
because classiﬁers are generated as a set of simple rules
without much sacriﬁce of accuracy [7]. Another advan-
tage  is that CAR mining algorithms can be applied not only
to  linearly separable cases, but also to linearly insepara-
ble cases, where LDA or other linear classiﬁcation methods
are  not applicable [8]. SVM can handle linearly inseparable
cases by mapping original data into a suitable feature space,
but  with loss of interpretability. Besides, especially when
applied  to gene expression data, CAR mining algorithms,
which predict a class label based on speciﬁc sets of differen-
tially  expressed genes that are actually observed in training
samples, are expected to generate more biologically rea-
sonable  classiﬁers, because it is generally not individual
genes but sets of genes that collectively deﬁne phenotypes
such as drug responses [9]. While applications of CBA and
its  variants in biological research have been reported in sev-
eral  reports [10–14], there is so far no reports with direct
implication for toxicogenomics, which is unique in that the
number  of variables to be analyzed is usually far much
greater in toxicogenomics (more than 30,000 genes) than
in  other applications and this so-called high dimensionality
makes it difﬁcult to analyze its data.
To compare the predictive performances and inter-
pretability of CBA and LDA, utilizing the TG-GATEs
database, where both microarray and toxicological data of
more  than 150 compounds in rats (in vivo and in vitro)
and  humans (in vitro) are stored, we built both CBA and
LDA  classiﬁers that predict whether a chemical compound
induces increases in liver weight after 14-day repetitive
treatments in rats based on transcriptomic data of 3-
day  repetitive treatments. Although measurable increases
in  mRNA (indicative of enzyme induction) are likely to
precede,  increase in liver weight is the most sensitive
indicator of hepatocellular hypertrophy and occur prior
to  morphological changes. While it should be also noted
that  hepatocellular hypertrophy without histological or
clinical  pathological alterations is considered to be an adap-
tive  non-adverse change, certain degrees of liver weight
increase appeared to be correlated with the subsequent
development of irreversible toxicity such as ﬁbrosis, necro-
sis,  vacuolization, fatty degeneration, and even neoplasia
[15] and early detection of hepatocellular hypertrophy
based on liver weight or gene expressions is expected to
be  useful, for example, in selecting compounds with less
risk  of hepatotoxicity in drug development.
2. Material and methods2.1.  Data source
TG-GATEs is a toxicogenomic database devel-
oped by The Toxicogenomics Project (TGP), a jointrts 1 (2014) 1133–1142
government-private sector project organized by the
National Institute of Biomedical Innovation, National Insti-
tute  of Health Sciences and 15 pharmaceutical companies
in  Japan, and The Toxicogenomics Informatics Project
(TGP2), a follow-on project from TGP organized by the
National Institute of Biomedical Innovation, National
Institute of Health Sciences and 13 companies. Gene
expression and toxicity data in vivo (rats) and in vitro
(primary cultured hepatocytes of rats and humans) after
treatments of more than 150 compounds are stored in the
TG-GATEs  database. TG-GATEs is now released for public
as  Open TG-GATEs (http://toxico.nibio.go.jp).
From  the TG-GATEs database, we used gene expression
data (n = 3 per group) one day after 3-day repetitive doses
(hereinafter 4D) in the liver of rats and liver weight data
(relative liver weights calculated from body weights) (n = 5
per  group) one day after 14-day repetitive doses (15D) in
rats  for this study. For each compound, only the data of
the  highest dose group and its control group was  used. Of
150  compounds, we  omitted one compound and analyzed
the  remaining 149 compounds because that one compound
was  found to have killed animals before 15D in the study
and  therefore no data is available for liver weight of 15D.
2.2.  CBA (classiﬁcation based on association)
2.2.1. Software
In  courtesy of Dr. Frans Coenen, we used a CBA program
available on the LUCS-KDD website, which is implemented
according to the original algorithm by [6], except that CARs
are  ﬁrst generated using the Apriori-TFP algorithm instead
of  the CBA-RG algorithm.
2.2.2.  Concept
The  basic concept of CBA is brieﬂy explained here based
on  the explanations from [6] with examples in this study.
For  detail, refer to [6]. Let D be the dataset, a set of records
d  (d ∈ D). Let I be the set of all non-class items in D, and Y be
the  set of class labels in D. In this study, a non-class item is
a  pair of gene ID and its discretized expression (Inc or Dec)
(Inc:  increased, Dec: decreased) and a class label is a pair
of  a target parameter (RLW: relative liver weight) and its
discretized value (Inc or NI, or Dec or ND) (NI: not increased,
ND:  not decreased). The set of class labels Y in this study is
either  {(RLW, Inc), (RLW, NI)} or {(RLW, Dec), (RLW, ND)}.
We  say that a record d ∈ D contains X ⊆ I, or simply X ⊆ d, if
d  has all the non-class items of X. Similarly, a record d ∈ D
contains  y ∈ Y, or simply y ⊆ d, if d has the class label y. A
rule  is an association of the form X → y (e.g. (Gene 01, Inc),
(Gene  02, Dec) → (RLW, Inc)). For a rule X → y, X is called an
antecedent of the rule and y is called a consequence of the
rule.  A rule X → y holds in D with conﬁdence c if c% of the
records in D that contain X are labeled with class y. A rule
X  → y has support s in D if s% of the records in D contain X
and  are labeled with class y. The objectives of CBA are (1)
to  generate the complete set of rules that satisfy the user-
speciﬁed minimum support (called minsup) and minimum
conﬁdence (called minconf) constraints, and (2) to build a
classiﬁer  from these rules (class association rules, or CARs).
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The original CBA algorithm of Liu et al. consists of two
arts, a rule generator (called CBA-RG) and a classiﬁer
uilder (called CBA-CB), each corresponding to (1) and (2).
The  key operation of CBA-RG is to ﬁnd all rules X → y
hat  have support above minsup. Rules that satisfy minsup
re  called frequent, while the rest are called infrequent. For
ll  the rulesthat have the same antecedent, the rule with
he  highest conﬁdence is chosen as the possible rule (PR)
epresenting this set of rules. If there are more than one
ules  with the same highest conﬁdence, one rule is ran-
omly  selected. If the conﬁdence is greater than minconf,
he  rule is accurate. The set of CARs thus consists of all
he  PRs that are both frequent and accurate. The CBA-RG
lgorithm effectively searches for all the CARs in a dataset
ased on the Apriori algorithm [16], assuming the down-
ard  closure property that for any X, X is frequent if and
nly  if any subset x of X is frequent. Instead of CBA-RG, the
oenen’s CBA program is implemented with the Apriori-
FP  algorithm [17,18], a variant of the Apriori algorithms
hat utilizes a tree-structured data representations for a
igher  performance.
The  operation of the latter part, CBA-CB, is described as
ollows  in [6]. “Given two rules, ri and rj, ri  rj (also called
i precedes rj or ri has a higher precedence than rj) if
.  the conﬁdence of ri is greater than that of rj, or
. their conﬁdences are the same, but the support of ri is
greater than that of rj, or
. both the conﬁdences and supports of ri and rj are the
same, but ri is generated earlier than rj.
Let R be the set of generated rules and D the training
ata”. CBA-CB is “to choose a set of high precedence rules
n  R to cover D”. A generated classiﬁer is of the form, <r1,
2, . . .,  rn, default class>, where ri, ∈ R and ra,  rb if b > a. In
lassifying a sample with a unknown class label, the ﬁrst
ule  that satisﬁes the sample will classify it. If there is no
ule  that applies to the sample, it takes on the default class,
efault  class. Below is a simple example of classiﬁers.
Example:
Gene 01, Inc) , (Gene 02, Dec) → (RLW, Inc)
Gene 01, Inc) , (Gene 03, Inc) → (RLW, Inc)
NULL) → (RLW, NI)
In this example. each line corresponds to a rule included
n  the classiﬁer. The rule with the (NULL) antecedent means
he  default rule of this classiﬁer. When a sample, (Gene 01,
nc),  (Gene 03, Inc) with an unknown class label (it is
nknown whether RLW is Inc or NI), is classiﬁed, the classi-
er  answers (RLW, Inc), as the second rule ﬁrst satisﬁes the
ample.  In another case, where a sample, (Gene 01, Inc),
Gene  02, Inc), is classiﬁed, the classiﬁer answers (RLW,
I),  as none of the rules except the default rule satisﬁes
he sample and thus the default rule is applied.rts 1 (2014) 1133–1142 1135
2.3. Data analysis
Prior  to the CBA analysis, we  have preprocessed gene
expression data in the liver (4D) and liver weight data (15D)
of  rats after repetitive doses for 149 compounds from the
TG-GATEs database. First, gene expressions were corrected
and  normalized by the MAS  5.0 algorithm [19] to reduce
inter-array variances [20]. Liver weights were transformed
into relative liver weight, a ratio of liver weight divided by
body  weight to avoid large variations in body weight ske-
wing  organ weight interpretation [15]. Second, values were
averaged  over individual animals included in each group.
Then,  for each compound-treated group, a fold change was
calculated  as a ratio of an average value of a treatment
group divided by an average value of its corresponding
control group, to reduce inter-study variances [21]. Finally,
we  discretized gene expressions and relative liver weights
based  on their fold changes (fc) and p values (p) of the
student’s t-test conducted between a compound-treated
group and its corresponding control group, according to
the  criteria shown below.
2.3.1.  Gene expression data
If fc > 2 and p < 0.05, assign “Inc” (increased).
If fc < 0.5 and p < 0.05, assign “Dec” (decreased).
Otherwise, assign “NC” (not changed).
2.3.2. Liver weight data
1.  When a classiﬁer for increased liver weight was built:If
fc > 1 and p < 0.05, assign “Inc” (increased).Otherwise,
assign “NI” (not increased).
2. When a classiﬁer for decreased liver weight was built:If
fc < 1 and p < 0.05, assign “Dec” (decreased).Otherwise,
assign  “ND” (not decreased).
Discretization thresholds for gene expressions com-
bined with fold changes and statistical test (e.g. student’s
t-test) have often been applied in microarray data analysis
and  is reported to be better than p value alone [22]. In gen-
eral,  numerical parameters obtained in toxicity studies are
judged  to be increased or decreased, based essentially on
statistical  comparison with contemporary controls and, if
available,  additionally on historical data [23]. In this study,
we  discretized liver weights based only on statistical tests,
as  no historical data was  available.
Before proceeding to CBA, gene expressions discretized
as “NC” in each group were discarded from the data,
because we  were interested only in genes with increased
or  decreased expressions. We  then analyzed the data with
CBA,  with discretized gene expressions as non-class items
and  discretized liver weights as class labels.
2.4. Linear discriminant analysis (LDA)
2.4.1. Software
We  used the lda function in the MASS library of R. R’s lda
function is implemented based on Rao’s LDA [24,25], also
known  as Fisher-Rao LDA, which generalized Fisher’s LDA
[26]  to multiple classes.
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2.4.2. Data analysis
Prior  to the LDA analysis, the data was preprocessed as
described in the CBA section, except that gene expressions
were not discretized. Before proceeding to LDA, the fea-
ture  selection step was conducted to reduce the number
of  genes, because classical LDA requires the total scatter
matrix to be nonsingular, while the matrix can be singular
when  the sample size (149) does not exceed the number
of  features (genes) (more than 30,000) [27], and tends to
overﬁt  and become less interpretable in the presence of
many  irrelevant and/or redundant features [28]. Based on
the  previous reports on microarray data analysis [29,30],
we  selected only the genes that were up-regulated (fc > 2
and  p < 0.05) or down-regulated (fc < 0.5 and p < 0.05) in
the  groups with increased or decreased liver weight when
compared to the not-increased or not-decreased groups,
respectively.
2.5.  Predictive performance comparison
To compare predictive performances of CBA and LDA,
we  conducted 10-fold cross validation [31] for each
methods with the total of 149 records (compounds), and
evaluated sensitivity, speciﬁcity, and accuracy averaged
over 10 validations. These parameters are deﬁned as
follows [32].
Sensitivity True positive/(true positive + false negative)
Speciﬁcity  True negative/(true negative + false positive)
Accuracy  (True positive + true negative)/total
10-fold cross validation, or more generally k-fold cross
validation, is one of the standard methods for evaluating
predictive performances of classiﬁers. This method divide
a  dataset into equally-sized k partitions (1, 2, . . .,  k). In the
ﬁrst  step, the ﬁrst partition (1) is reserved as a test set and
the  other partitions (2, 3, . . .k) are used as a training set to
build  a classiﬁer. Once a classiﬁer is built, it is validated for
its  predictive performances with a test set (the ﬁrst parti-
tion  in this case). k-Fold cross validation repeats this steps k
times  changing a partition serving as a test set one by one.
In  the end, averaged predictive performance over k vali-
dation  steps is regarded as the predictive performance of a
classiﬁcation  algorithm.
2.6. Student’s t-test
For  statistical comparison of mean gene expressions
or liver weights between a compound-treated group and
its  corresponding control group for each compound, the
unpaired  two tailed student’s t-test without equal variance
assumption was conducted. Speciﬁcally, this statistical test
was  conducted in the discretization step of CBA and the
feature  selection step of LDA. When gene expressions were
compared between two groups, gene expressions were log-
transformed with base of two prior to the statistical test.
Log  transformations of gene expression data is known to
result  in more consistent statistical inferences and be often
considered desirable, due to its large coefﬁcient of variation
[33].rts 1 (2014) 1133–1142
It  is well known that the standard p-value method leads
to  the high rate of false positives when applied in repeated
testing. This is the case when analyzing gene expression
data collected via microarrays, as this usually involves
testing from several thousands to tens of thousands of
hypotheses simultaneously. While a number of adjustment
procedures (e.g. controlling the false discovery rate) are
available, they are often too conservative for microarray
studies in that they can lead to low sensitivity [34], thus
increasing the risk of missing true positives. In this study,
no  adjustments were applied, taking it into consideration
that even if false positive genes with no or little relevance
for liver weights were detected by statistical tests, the clas-
siﬁcation  methods would discard many of them from a
generated classiﬁer, hence marginalize the impact of such
false  positives while minimizing the risk of overlooking
true important changes.
2.7.  Pathway analysis
Canonical  pathway analysis for the genes included in
the  CBA-generated classiﬁer was conducted with QIAGEN’s
Ingenuity Pathway Analysis (IPA) software to understand
what pathway (and hence function) these genes are mainly
involved. The reason why  we used IPA, not a publicly avail-
able  database, is its high quality of information. IPA is based
on  “expertly curated biological interactions and func-
tional annotations from millions of individually modeled
relationships between proteins, genes, complexes, cells,
tissues,  drugs, and diseases” and “reviewed for accu-
racy by PhD scientists” (according to QIAGEN’s website:
http://www.ingenuity.com/products/ipa).
Canonical pathways are a set of pre-built pathways
based on the literature. Canonical pathway analysis of IPA
answers  how statistically signiﬁcantly the pathways were
affected,  considering how many molecules a user-speciﬁed
set and a pathway share. In this study, we conducted
canonical pathway analysis with all the genes included in
our  CBA-generated classiﬁer. In canonical pathway analy-
sis,  speciﬁed genes are converted to their corresponding
molecules and matched up against the molecules in each
pathway.
2.8.  Computer
In  this study, we  used a personal computer with Intel
Core i5-3320M 2.6 GHz CPU and 4 GB RAM for the analyses.
3.  Results
3.1. Selection of minimum support and conﬁdence
In CBA, a user must specify two  parameters: minimum
support (minsup) and minimum conﬁdence (minconf).
There is no universal criteria for these parameters. In
this  study, we  assumed that lower minsup and higher
conﬁdence are basically desirable. That is to say, a rule
is  considered useful, if the rule X → y satisﬁes a large
fraction of records that matches the rule antecedent X,
even  if the number of records that matches X is small. This
is  because a drug-induced response (or more generally
K. Nagata et al. / Toxicology Repo
Table 1
Exploration of various CBA settings.
minsup (%) minconf (%) Average accuracy (%) Total time (s)
(A) When minsup was  ﬁxed at 10%
10 50 77 0.61
10  80 76 0.59
10  90 79 0.58
10  100 77 0.58
(B)  When minconf was  ﬁxed at 90%
20 90 0 0.42
15  90 9 0.42
10  90 79 0.58
8  90 83 22.37
7  90 Insufﬁcient memory
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wccuracy of CBA classiﬁers for increased relative liver weight was evalu-
ted in 10-fold cross validations under various combinations of minsup
nd minconf.
iological response) is considered to be not caused by a
ingle  mechanism. Rather, it is expected that there are
everal different mechanisms, thus different gene expres-
ion  patterns, ﬁnally leading to the target drug-induced
esponse, and that each gene expression pattern occurs
n  a relatively low frequency among the dataset even if
he  dataset contains an enough records with the target
rug-induced response. If set too strict, however, there is
 risk of missing useful rules with few exceptions for too
igh  minconf and of selecting accidental rules with only
 few satisfying records for too low minsup. Moreover,
insup is also limited by computational resources, as the
ower  the minsup is set, the higher the computational
emand is, in terms of both time and memory.
To explore the ideal settings of minsup and minconf,
e evaluated accuracy of CBA classiﬁers for increased liver
eight  in 10-fold cross validations under various combi-
ations of minsup and minconf (Table 1). First, we ﬁxed
he  minsup at 10% and changed the minconf from 50% to
00%.  While the minconf at 90% marked the highest accu-
acy  (79%), there were no obvious differences or tendency
n  accuracy among the different minconfs. Next, we  ﬁxed
he  minconf at 90% and changed the minsup from 20%
ownward. Lowering the minsup remarkably improved
ccuracy, but prolonged computational time at the same
ime.  The accuracy reached at 83% with minsup at 8%. We
ried  with minsup at 7%, but failed to ﬁnish the computa-
ion due to memory insufﬁciency. Similar tendencies were
lso  conﬁrmed when assessing accuracy of classiﬁers for
ecreased  liver weight under different minsups and min-
onfs  (data not shown).
Based  on these results, we adopted the minsup at 8%
nd  minconf at 90% for the following analyses.
.2. Predictive performance
We  compared predictive performance of classiﬁers
etween CBA and LDA with 10-fold cross validation
Table 2). When increased liver weight was targeted (that
s,  when a classiﬁer for increased liver weight was built),
BA  outperformed LDA in all of the three criteria: accuracy
83%  for CBA vs. 75% for LDA), sensitivity (82% vs. 72%),
nd speciﬁcity (85% vs. 75%). When decreased liver weight
as  targeted, CBA scored better accuracy (86% vs. 73%)rts 1 (2014) 1133–1142 1137
and  sensitivity (22% vs. 6%), while LDA marked better
speciﬁcity (90% vs. 95%).
We also compared between CBA and CBA-DR (CBA with-
out  default rule), our modiﬁed version of the original CBA
(Table  2). CBA-DR does not predict if a sample does not
match  any rule except the default rule in a classiﬁer, and, in
turn,  return a ‘hold’. When increased liver weight was tar-
geted,  CBA-DR marked lower accuracy (83% for CBA vs. 79%
for  CBA-DR) and speciﬁcity (85% vs. 29%) and higher sen-
sitivity  (82% vs. 100%). When decreased liver weight was
targeted, CBA-DR marked lower sensitivity (22% for CBA
vs.  0% for CBA-DR) and higher accuracy (86% vs. 95%) and
speciﬁcity (90% vs. 100%).
3.3.  Interpretability
We  compared the form of generated classiﬁers between
CBA and LDA (Fig. 1), when all the records were used as a
training  set for increased liver weight. CBA tells us a set of
rules,  arranged in order of conﬁdence. Each rule consists of
an  antecedent, which is an itemset in the form of (non-class
attribute, its discretized value), and a consequence in the
form  of (class attribute, its class label), shown after “−>”
here.
On  the other hand, LDA tells us a single discriminative
function (fd), which is a polynomial of non-class attribute
values with their coefﬁcients. Coefﬁcients in a discrimina-
tive function of LDA reﬂect discriminative power of each
non-class attribute (gene, here), with higher positive values
and  lower negative values meaning larger contributions
to each corresponding class label of a class attribute (liver
weight, here).
3.4.  Biological relevance
To  look into how biologically reasonable the CBA-
generated classiﬁer is, we  conducted the canonical
pathway analysis for the set of genes selected in the clas-
siﬁer  when all the records were used as a training set for
increased liver weight (Table 3) (for brevity, only top 10
pathways in order of −log p are shown). Because LDA itself,
in  contrast to CBA, does not explicitly select a set of genes
in  building a classiﬁer, we  did not compare CBA with LDA
here.
We  could assume that the most signiﬁcant pathways
involved with the genes in our classiﬁer were mainly drug
metabolism-related ones, such as Xenobiotic Metabolism
Signaling, LPS/IL-1 Mediated Inhibition of PXR Function,
PXR/RXR Activation etc.
Fig. 2A is an excerpt around the NRF2 molecule from
the illustration of the Xenobiotic Metabolism Signaling
pathway, exported from IPA. NRF2 is a key modulator of
oxidative stress responses. In response of oxidative stress,
NRF2  is released into the nucleus and up-regulates down-
stream antioxidant enzymes, mainly drug metabolism
enzymes. Actually, the genes of drug metabolism enzymes
such  as GST, NQO, and UGT downstream of NRF2 were
included in our classiﬁer, suggesting the induction of
drug  metabolism enzymes triggered by NRF-2-dependent
oxidative stress responses.
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Table 2
Comparison of predictive performances.
Method Target direction Average over 10-fold cross validation
Total TP FN FP TP Hold Accuracy (%) Sensitivity (%) Speciﬁcity (%)
CBA Inc 14.9 4.4 1.1 1.4 8 – 83 82 85
LDA Inc 14.9 2.7 1 2.8 8.4 – 75 72 75
CBA-DR Inc 14.9 4.4 0 1.4 0.8 8.3 79 100 29
CBA Dec 14.9 0.2 0.7 1.4 12.6 – 86 22 90
LDA Dec 14.9 0.2 3.3 0.7 10.7 –  73 6 95
CBA-DR Dec 14.9 0  0.7 0 12.6 1.6 95 0 100
Predictive performance of classiﬁers was compared among CBA, LDA, CBA-DR with 10-fold cross validation.
Target  direction: a classiﬁer was built for whether increased (Inc) or decreased (Dec) relative liver weight. Total: average number of total records in a test
set  of each trial in a cross validation. TP: average number of true positive records in a test set. FN: average number of false negative records in a test set. FP:
average  number of false positive records in a test set. TN: average number of true negative records in a test set. Hold: average number of records in a test
set  that did not match any rules except the default rule (only for CBA-DR).
Note that accuracy, sensitivity and speciﬁcity for the CBA-DR method were calculated excluding ‘hold’ samples. Totals are not integers here, as the number
of  records in the original dataset was 149 and thus cannot be divided by 10, the number of trials in the cross validation.
CBA
(1368121_at,  Inc), (1381852_at,  Inc)  -> (RLW, Inc),  Suppo rt:  13 .4% , Con fiden ce: 100 .0%
(1387022_at,  Inc), (1370067_at,  Inc)  -> (RLW, Inc),  Suppo rt:  11 .4% , Con fiden ce: 100 .0%
(1368905_at,  Inc), (1387783_a_a t, Inc)  -> (RLW, Inc),  Suppo rt:  10 .7% , Con fiden ce: 100 .0%
(1371076_at,  Inc), (1370828_at,  Inc)  -> (RLW, Inc),  Support : 9.4% , Con fiden ce: 100 .0%
(1371089_at,  Inc), (1368905_at,  Inc), (1387599_a_a t, Inc)  -> (RLW, Inc),  Support : 8.7% , Con fiden ce: 100 .0%
(1368905_at,  Inc), (1375845_at,  Inc)  -> (RLW, Inc),  Support : 8.7% , Con fiden ce: 100 .0%
(1368905_at, Inc), (1371076_at, Inc), (1371143_at, Inc) -> (RLW, Inc), Support: 8.1%, Confidence: 100.0%
(1368905_at,  Inc), (1390145_at,  Dec), (1387006_a t, Inc)  -> (RLW, Inc),  Support : 8.1% , Con fiden ce: 100 .0%
(1371076_at,  Inc), (1387307_at,  Dec)  -> (RLW, Inc),  Support : 8.1% , Con fiden ce: 100 .0%
(1370698_at,  Inc), (1381852_at,  Inc)  -> (RLW, Inc),  Support : 10 .7% , Con fiden ce: 94 .1%
(1387022_at,  Inc), (1371076_at,  Inc), (1384225_at,  Dec)  -> (RLW, Inc),  Support : 10 .1% , Con fiden ce: 93 .8%
(1369440_at,  Dec)  -> (RLW, Inc),  Support : 10 .1% , Con fiden ce: 93 .8%
(1377599_at,  Inc)  -> (RLW, NI),  Support : 9.4% , Con fiden ce: 93 .3%
(1373814_at,  Dec), (1389253_at,  Inc)  -> (RLW, Inc),  Support : 8.1% , Con fiden ce: 92 .3%
(1371089_at,  Inc), (1368905_at,  Inc), (1371942_at,  Inc)  -> (RLW, Inc),  Support : 8.1% , Con fiden ce: 92 .3%
(NULL)  -> (RLW, NI)
LDA
fd = 1.0982  fc(1380013_ at) + 0.6116  fc(1387740 _at) + 0.4895  fc(1389253_a t) + 0.4870  fc(1368317 _at)
+ 0.4471  fc(1370870 _at) + 0.4202  fc(1374187_a t) + 0.2830  fc(1387766 _a_ at) + 0.2012  fc(1390358 _at)
+ 0.1999  fc(1371076 _at) + 0.1195  fc(1369759_a t) + 0.1109  fc(1384431 _at) + 0.0638  fc(1387936_a t)
+ 0.0317  fc(1382137 _at) + 0.0292  fc(1368905_a t) + 0.0126  fc(1369698 _at) + 0.0081  fc(1368718_a t)
+ 0.0063  fc(1369921 _at) + 0.0041  fc(1370269_a t) + 0.0039  fc(1387022 _at) + 0.0024  fc(1374070_a t)
+ 0.0023 fc(1387100_at) + 0.0002 fc(1398250_at) - 0.0003 fc(1387825_at) - 0.0034 fc(1385247_at)
- 0.0055  fc(1370491 _a_ at)  - 0.0124  fc(1371089_ at)  - 0.0180  fc(1380669_ at)  - 0.0723  fc(1370902 _at)
- 0.1127  fc(1392413 _at)  - 0.1159  fc(1388211 _s_at)  - 0.1487  fc(1388210 _at)  - 0.2057  fc(1387574 _at)
- 0.2170 fc(1380536_at) - 0.2384 fc(1375845_at) - 0.3318 fc(1389179_at) - 0.4109 fc(1378169_at)
- 0.4740  fc(1395403 _at)  - 0.6657  fc(1391544 _at) + 3.438 9
If fd > 0,  pred icts RLW as Inc.
Else, RLW as NI.
Antecedent: a  set of non-
class item s in the form of 
(gene_id, Inc or Dec)
Consequ ence: a cl ass label 
as predic on result in the 
form of (RLW, Inc or NI)
Supp ort and  
Conﬁdence of the rule
The ﬁrst rule that sa sﬁes the sample cl assiﬁes it. If there is no rule sa sfying the sample , 
the ﬁnal default rule, (NULL ), is appli ed. 
In LDA, a cl ass iﬁer is represented by a discri mina ve fun con, fd, whic h is a polynomial of 
non-class aribute values (fold changes) with their coeﬃcients
In
 C
BA
, a
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la
ss
iﬁ
er
 is
 a
 se
t o
f r
ul
es
 (e
ac
h 
lin
e)
.
If the discriminave fun con is posive, the cl assiﬁer predic ts 
RLW as Inc. Otherwise, RLW as NI.
Fig. 1. Comparison of the classiﬁer form between CBA and LDA. The form of generated classiﬁers were compared between CBA and LDA, when all the records
were  used as a training set for increased relative liver weight. [CBA] The classiﬁer consists of a set of rules, represented as “antecedent → consequence, support,
conﬁdence”,  one rule par line, in order of conﬁdence. An antecedent is a set of non-class items, each item represented as (gene id, Inc or Dec). A consequence
is  a class label that is used as a classiﬁcation result if the corresponding antecedent is satisﬁed, shown here as (RLW, Inc or NI). The ﬁnal rule with an
antecedent  (NULL) is the default rule, which is satisﬁed for any records and applied if all the preceding rules are not met. [LDA] The classiﬁer is shown as a
discriminative  function, fd. fc(gene id) is a fold change of a gene speciﬁed with gene id. If fd is positive, the classiﬁer predicts RLW as Inc. Otherwise, RLW
as  NI. gene id: Represented here as an Affymetrix probe ID. RLW: relative liver weight. Inc: increased. Dec: decreased. NI: not increased.
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Table 3
Canonical pathway analysis of CBA classiﬁer.
Pathway Name −log p Molecules Corresponding Genes
Total Inc Dec
Xenobiotic metabolism signaling 8.96 219 8 0 Gsta3, Aldh1a1, Ugt2b1,
Nqo1,RGD1559459, Cyp2b2, Ces2c,
Sult2a2
LPS/IL-1 mediated inhibition of RXR function 5.07 178 4 1 Abccg8, Gsta3
PXR/RXR  activation 3.95 58 3 0 Aldh1a1, Cyp2b2, Sult2a2
Aryl  hydrocarbon receptor signaling 2.94 127 3 0 Gsta3, Aldh1a1, Nqo1
Nicotine  Degradation III 2.77 37 2 0 Ugt2b1, Cyp2b2
Melatonin  Degradation I 2.75 38 2 0 Ugt2b1, Cyp2b2
Serotonin  degradation 2.67 42 2 0 Aldh1a1, Ugt2b1
Superpathway of melatonin degradation 2.67 42 2 0 Ugt2b1, Cyp2b2
NRF2-mediated oxidative stress response 2.66 159 3 0 Gsta3, Akr7a3, Nqo1
Nicotine  Degradation II 2.65 43 2 0 Ugt2b1, Cyp2b2
Histidine  Degradation III 2 6 0 1 Hal
The canonical pathway analysis was conducted with the Ingenuity IPA software for the genes included in the CBA classiﬁer when all the records were used
as  a training set for increased relative liver weight. Note that, for brevity, only top 10 pathways in order of -logp are shown here.
− the anal
i  (upreg
e for the i
w
t
m
e
a
F
S
e
b
c
olog  p: −log of p, where p is a value representing statistical signiﬁcance in 
s  more statistically signiﬁcantly involved. Molecules: the total, increased
ach  pathway are shown. Corresponding genes: corresponding rat genes 
Fig. 2B shows overlapping among the canonical path-
ays detected as signiﬁcant, which were divided intohree  clusters. The largest cluster consists of drug
etabolism-related pathways as described above. Inter-
stingly, two other clusters, histidine degradation-related
nd gluconeogenesis-related, were also detected with no
ig. 2. Canonical pathway illustrations of CBA classiﬁer. [A] An excerpt around
ignaling  pathway, exported from IPA. [B] Overlapping among the canonical pa
xported  from IPA. Each node corresponds to each canonical pathway detected 
etween  two pathways. Color depth of nodes corresponds to the −log p value (
orresponds to the number of molecules shared between two pathways (no line 
f  the references to color in this ﬁgure legend, the reader is referred to the web vysis. A smaller p value (thus a larger −log p value) means that the pathway
ulated) number and decreased (downregulated) number of molecules in
ncreased or decreased molecules included in the pathway are shown.
overlap  between the drug metabolism-related cluster and
them.We  then summarized Affymetrix probe IDs, gene sym-
bols  and gene names for each gene in our classiﬁer and
divided them into four categories, drug metabolism, gluco-
neogenesis, histidine degradation and the other (Table 4),
 the NRF2 molecule from the illustration of the Xenobiotic Metabolism
thways detected as signiﬁcant, which were divided into three clusters,
as signiﬁcant. Each link corresponds to the number of molecules shared
the deeper depth is, the larger the −log p values is). Line width of links
means no shared molecules between two  pathways). (For interpretation
ersion of this article.)
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Table 4
Details and category of the genes in our CBA classiﬁer.
Affymetrix probe ID Gene symbol Changedirection Gene name or detail
Drug metabolism
1368121 at Akr7a3 Inc Aldo-keto reductase family 7, member A3 (aﬂatoxin aldehyde reductase)
1381852  at RGD1559459 Inc Similar to Expressed sequence AI788959 (Ugt2b34, Mus  musculus)
1387022  at Aldh1a1 Inc Aldehyde dehydrogenase 1 family, member A1
1368905 at Ces2C Inc Carboxylesterase 2C
1371076 at Cyp2b2 Inc Cytochrome P450, family 2, subfamily b, polypeptide 2
1371089  at Gsta3 Inc Glutathione S-transferase alpha 3
1387599 a at Nqo1 Inc NAD(P)H dehydrogenase, quinone 1
1370698 at Ugt2b1 Inc UDP glucuronosyltransferase 2 family, polypeptide B1
1387006  at Sult2a2 Inc Sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 2
1371942 at Gstt3 Inc glutathione S-transferase, theta 3
Gluconeogenesis
1370067 at Me1  Inc Malic enzyme 1, NADP(+)-dependent, cytosolic
Histidine degradation
1387307 at Hal Dec Histidine ammonia-lyase
Other
1387783 a at Acaa1b Inc Acetyl-Coenzyme A acyltransferase 1B
1370828 at Zdhhc2 Inc Zinc ﬁnger, DHHC-type containing 2
1375845 at Aig1 Inc Androgen-induced 1
1371143  at Serpina7 Inc Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7
1390145 at Dmxl2 Dec Dmx-like 2
1384225 at (NA) Dec (NA)
1369440 at Abcg8 Dec ATP-binding cassette, subfamily G (WHITE), member 8
1377599  at Lpin1 Inc Lipin 1
1373814 at R3hdm2 Dec R3H domain containing 2
1389253  at Vnn1 Inc Vanin 1
Affymetrix probe IDs, gene symbols and gene names for each gene in our CBA classiﬁer are summarized. The genes are divided into four categories, drug
metabolism,  gluconeogenesis, histidine degradation and the other.
: not avChange direction: the direction of change (Inc or Dec) in the classiﬁer. NA
probe  ID, 1384225 at.
based on the canonical pathway analysis. Of 22 genes, 10
genes  were drug metabolism-related.
Our  classiﬁer was shown again, with genes converted
from Affymetrix probe IDs to gene symbols and colored
according to their category (Fig. 3). The mostly drug
metabolism-related nature of our classiﬁer was conﬁrmed,
as  most of the rules in the classiﬁer included drug one or
more  metabolism-related genes (shown in red).
(Akr7a 3, Inc), (RGD155945 9, Inc)  -> (RLW
(Aldh1a 1, Inc), (Me1, Inc)  -> (RLW
(Ces2c, Inc), (A caa1b , Inc)  -> (RLW
(Cyp2b 2, Inc), (Zdhh c2, Inc)  -> (RLW
(Gsta3, Inc), (Ces2c, Inc), (Nqo 1, Inc)  -> (RLW
(Ces2c, Inc), (A ig1 , Inc)  -> (RLW
(Ces2c, Inc), (Cyp2b 2, Inc), (S erpina7 , Inc)  -> (RLW
(Ces2c, Inc), (Dmxl2, Dec), (Sult2a 2, Inc)  -> (RLW
(Cyp2b 2, Inc), (Hal, Dec)  -> (RLW
(Ugt2b 1, Inc), (RGD155945 9, Inc)  -> (RLW
(Aldh1a 1, Inc), (Cyp2b 2, Inc), (1384225_at,  Dec)  -> (RLW
(Abcg8, Dec) -> (RLW
(Lp in1 , Inc)  -> (RLW
(R3hd m2, Dec), (Vnn1 , Inc)  -> (RLW
(Gsta3, Inc), (Ces2c, Inc), (Gstt 3, Inc)  -> (RLW
(NULL)  -> (RLW
Fig. 3. Our CBA Classiﬁer with Categorized Gene Symbols. The CBA classiﬁer, th
Affymetrix  probe IDs to gene symbols and colored according to their category
histidine  degradation-related. Black: Other. (For interpretation of the references 
this  article.)ailable. No further information is available for the gene with Affymetrix
4.  Discussion
When increased liver weight was targeted, CBA out-
performed LDA in all of the three criteria: accuracy,
sensitivity, and speciﬁcity. In contrast, when decreased
liver weight was targeted, both CBA and LDA scored low
sensitivities and high speciﬁcities. These tendencies are
attributable to the low frequency of decreased liver weight
, Inc),  Suppo rt:  13 .4% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  11 .4% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  10 .7% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  9.4% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  8.7% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  8.7% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  8.1% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  8.1% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  8.1% , Con fiden ce = 100 .0%
, Inc),  Suppo rt:  10 .7% , Con fiden ce = 94 .1%
, Inc),  Suppo rt:  10 .1% , Con fiden ce = 93 .8%
, Inc), Support: 10.1%, Confidence = 93.8%
, NI),  Suppo rt:  9.4% , Con fiden ce = 93 .3%
, Inc),  Suppo rt:  8.1% , Con fiden ce = 92 .3%
, Inc),  Suppo rt:  8.1% , Con fiden ce = 92 .3%
, NI)
e same as one in Fig. 1, is shown again, with the genes converted from
. Red: drug metabolism-related. Blue: gluconeogenesis-related. Green:
to color in this ﬁgure legend, the reader is referred to the web version of
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n the data set. For such a data set, a classiﬁer returning a
egative  answer (i.e. no for decreased liver weight) with
 high frequency, regardless of predictivity, can score a
ood  speciﬁcity but a poor sensitivity. Except for such an
mbalanced data set, CBA succeeded in building a better
redictive classiﬁer than LDA in this study. This superior-
ty  of CBA over LDA is considered to reﬂect the non-linear
ature of the data set. Generally, a drug-induced response
or  more generally biological response) is considered to be
aused  not by the single mechanism, but by several dif-
erent  mechanisms. Thus, there are several different, not
ecessarily linearly separable, gene expression patterns
hat  ﬁnally lead to the same response (e.g. increased liver
eight). In this light, CBA is likely to build a better clas-
iﬁer for a data set in toxicology, or more broadly biology,
han  LDA, as CBA can captures linearly inseparable patterns
esiding in the data set.
We  also compared between CBA and CBA-DR, our mod-
ﬁed  version of the original CBA. When increased liver
eight was targeted, CBA-DR marked lower accuracy than
BA.  Interestingly however, CBA-DR marked 100% sensi-
ivity.  This can be said as follows: if CBA returns an “Inc”
nswer for liver weight and we know the default rule is not
pplied  in the classiﬁcation process, we can say that liver
eight  would be increased with higher conﬁdence than if
e  don’t know whether the default rule is applied or not. In
ddition,  we can also infer how reliable the classiﬁcation is
n  CBA when non-default rule is met, based on its support
nd  conﬁdence. Therefore, CBA offers not only a classi-
cation result, but also additional information regarding
eliability of classiﬁcation. This can be another advantage
f  CBA over LDA, which returns only a classiﬁcation result.
In  terms of interpretability, while both CBA and LDA give
s  information regarding important genes which can dis-
riminate  increased liver weights well, LDA does not take
he  concept of co-expression into account. For example,
n  our setting, a rule (1368905 at, Inc) occurred 6 times
n  the CBA-generated classiﬁer. This rule, however, always
ccurred with other rules, reﬂecting the pattern actually
bserved in the training data set. Therefore, even if the
ene,  1368905 at, is highly increased in an unknown sam-
le,  it does not necessarily mean increased liver weight.
uch co-expressed pattern was not taken into account by
DA.  Besides, while coefﬁcient values are useful to infer
mportance of each gene in LDA, the ﬁnal prediction is
etermined by the total of all the terms in a polynomial, not
y  a single or small set of genes. The classiﬁcation process of
BA  is much simpler and easy to understand, because each
ule  is as simple as a single or small set of genes and the
rediction is determined once a rule is satisﬁed, regardless
f  the other genes. This characteristic of CBA makes a gen-
rated  classiﬁer easy to understand, even for a non-expert
ser, because a CBA-generated classiﬁer can be expressed
lso  in a natural language (e.g. “If gene A is increased and
ene  B is decreased, then the classiﬁer predicts liver weight
o  be increase”), not in a mathematical equation as is case
n  LDA.Canonical pathway analysis with IPA revealed that
he genes included in our CBA-generated classiﬁer for
ncreased liver weight were mostly drug metabolism-
elated ones. This is reasonable as inductions of hepaticrts 1 (2014) 1133–1142 1141
drug metabolizing enzymes are well known to induce
hepatocellular hypertrophy [35], of which increases in
liver  weight is the most sensitive indicator [15]. CBA suc-
ceeded  in building a biologically relevant classiﬁer without
any  prior knowledge such as literature. Intriguingly, the
classiﬁer included genes with other functions such as glu-
coneogenesis and histidine degradation, which are not
directly  related to increased liver weight or hepatocellu-
lar hypertrophy. While it is unclear whether these genes
were  actually causal or not, CBA can be used to look for
genes  with an unknown function but high correlation for
a  speciﬁed outcome as well as to build a biologically rea-
sonable  classiﬁers. In addition, it was  also considered to be
an  advantage that CBA automatically selects a small set of
genes  to build a classiﬁer, while LDA does not.
5. Conclusions
We  applied the CBA algorithm to the TG-GATEs
database, where both toxicogenomic and other toxicolog-
ical  data of more than 150 compounds in rat and human
are  stored, to build a predictive classiﬁer of increased or
decreased liver weight for an unknown compound. We
compared the generated classiﬁers between CBA and LDA,
and  showed that CBA is superior to LDA in terms of both
predictive performances and interpretability.
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